Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NeoPep Vaccine1 + Poly-ICLC
- Development stage
- Unknown
- Lead developer
- Hangzhou Neoantigen Therapeutics
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
NeoPep Vaccine1 + Poly-ICLC is a combination immunotherapy under investigation for the treatment of glioblastoma and other cancers. NeoPep Vaccine1 (NPVAC1) consists of up to five synthetic peptides derived from human cytomegalovirus (HCMV) antigens, designed to stimulate an immune response against tumor cells. It is administered in combination with Poly-ICLC, a stabilized form of polyinosinic-polycytidylic acid that acts as an immune adjuvant by mimicking viral double-stranded RNA and activating innate immunity through Toll-like receptor 3 (TLR3) and melanoma differentiation-associated protein 5 (MDA5). This activation leads to the production of type I interferons and pro-inflammatory cytokines, enhancing antigen presentation and promoting T-cell mediated anti-tumor responses. The combination aims to induce robust tumor-specific T cell populations in patients with newly diagnosed glioblastoma[5][6][7].
- Other names
- NeoPep Vaccine1 plus Poly-ICLCNPVAC1 plus Poly ICLCNPVAC-1 plus Poly ICLCNPVAC 1 plus Poly ICLC
02
Targets
IFIH1 (MDA5)MHC II (Major histocompatibility complex class II receptor)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on NeoPep Vaccine1 + Poly-ICLC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeoPep Vaccine1 + Poly-ICLC.